Rapid on-site diagnosis of PEDV and PoRV co-infection by gold magnetic nanoparticles-based SERS immunochromatography.

Porcine epidemic diarrhea virus (PEDV) and porcine rotavirus (PoRV) are the two main pathogens causing porcine diarrhea, which are characterized by high morbidity and mortality. Most of the diagnostic methods available are limited to the laboratory or fail to highlight their advantages in terms of target species, detection time, sensitivity, and stability. To meet the demand for rapid on-site diagnosis of PEDV and PoRV co-infection, a surface-enhanced Raman scattering (SERS) immunochromatographic sensor based on gold magnetic nanoparticles (MNPs) was developed.

MLLT3 Regulates Melanoma Stemness and Progression by Inhibiting HMGB1 Nuclear Entry and MAGEA1 MC Modification.

Melanoma stem cells are a kind of cells with self-renewal and multi-directional differentiation potential. They are one of the key factors in the occurrence, development and metastasis of melanoma. This study demonstrates that MLLT3 is a transcription factor that regulates the stemness and progression of melanoma.

Effect of home-based transcranial direct current stimulation (tDCS) on cognitive functioning in bipolar depression.

Bipolar depression is commonly accompanied by cognitive impairments. Transcranial direct current stimulation (tDCS) is emerging as a novel non-invasive treatment for bipolar depression. Given the portability and safety of tDCS, we developed a home-based protocol with real-time supervision.

LcMYB5, an R2R3-MYB family gene from Lonicera caerulea L., enhances drought and salt tolerance in transgenic tobacco and blue honeysuckle.

MYB transcription factors exert crucial functions in enhancing plant stress tolerance, which is impacted by soil drought and salinity. In our study, the R2R3-type MYB transcription factor gene LcMYB5 from blue honeysuckle (Lonicera caerulea L.) was successfully cloned and identified, and confirmed its nuclear localization.

Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024.

Background: Ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, is a widely used treatment for various dermatological diseases. This study employs the FDA Adverse Event Reporting System (FAERS) database to examine adverse events (AEs) associated with ruxolitinib cream.

Methods: This study employed disproportionate analysis methods, including reported odds ratio and proportional reporting ratio, to collate AEs reported from the fourth quarter of 2021 to the first quarter of 2024.